SALV Salvarx Group Plc

TIDMSALV

RNS Number : 5048K

SalvaRx Group plc

14 December 2018

14 December 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Nominated Adviser Status

SalvaRx announces that the Directors have been advised by its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland"), of its proposed merger with SP Angel Corporate Finance LLP ("SP Angel"). Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7.00 a.m. on 1 February 2019.

As a result, it is the intention of the Directors to transition the Company's Nomad role from Northland to SP Angel. This process has already started and at present the Directors anticipate a smooth and orderly transition of the Nomad role.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a replacement Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. In the event that the Company has failed to appoint a replacement Nomad by 4 March 2019, the admission of its AIM Securities will be cancelled.

Enquiries:

 
 SalvaRx Group plc 
 Ian Walters (Chief Executive)                  Tel: +1 203-441-5451 
 Northland Capital Partners Limited                  Tel: +44 (0) 20 
  Nominated Adviser and Broker                             3861 6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 Peterhouse Capital Limited                          Tel: +44 (0) 20 
  Joint Broker                                             7469 0932 
  Lucy Williams / Duncan Vasey 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUSSBRWWAUARA

(END) Dow Jones Newswires

December 14, 2018 02:50 ET (07:50 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Nov 2024 to Dec 2024

Salvarx (LSE:SALV)
Historical Stock Chart
From Dec 2023 to Dec 2024